| __timestamp | Amicus Therapeutics, Inc. | Xenon Pharmaceuticals Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 20717000 | 5496000 |
| Thursday, January 1, 2015 | 47269000 | 9786000 |
| Friday, January 1, 2016 | 71151000 | 6792000 |
| Sunday, January 1, 2017 | 88671000 | 7313000 |
| Monday, January 1, 2018 | 127200000 | 8382000 |
| Tuesday, January 1, 2019 | 169861000 | 10803000 |
| Wednesday, January 1, 2020 | 156407000 | 12944000 |
| Friday, January 1, 2021 | 192710000 | 21967000 |
| Saturday, January 1, 2022 | 213041000 | 32810000 |
| Sunday, January 1, 2023 | 275270000 | 46542000 |
Igniting the spark of knowledge
In the competitive landscape of biotechnology, managing operational expenses is crucial for sustainable growth. This analysis delves into the Selling, General, and Administrative (SG&A) expenses of two prominent players: Amicus Therapeutics, Inc. and Xenon Pharmaceuticals Inc., from 2014 to 2023.
Amicus Therapeutics has seen a significant rise in SG&A expenses, growing by over 1,200% from 2014 to 2023. This increase reflects their aggressive expansion and investment in administrative capabilities. By 2023, their SG&A expenses reached a peak, indicating a strategic focus on scaling operations.
In contrast, Xenon Pharmaceuticals maintained a more conservative growth in SG&A expenses, with a 750% increase over the same period. This suggests a more measured approach to scaling, potentially focusing on efficiency and cost management.
Understanding these trends offers valuable insights into each company's strategic priorities and operational efficiency.
Operational Costs Compared: SG&A Analysis of AstraZeneca PLC and Xenon Pharmaceuticals Inc.
Comparing SG&A Expenses: Regeneron Pharmaceuticals, Inc. vs Amicus Therapeutics, Inc. Trends and Insights
GSK plc vs Amicus Therapeutics, Inc.: SG&A Expense Trends
Operational Costs Compared: SG&A Analysis of BeiGene, Ltd. and Xenon Pharmaceuticals Inc.
Cost Management Insights: SG&A Expenses for Neurocrine Biosciences, Inc. and Xenon Pharmaceuticals Inc.
Who Optimizes SG&A Costs Better? Insmed Incorporated or Xenon Pharmaceuticals Inc.
Cost Management Insights: SG&A Expenses for Dr. Reddy's Laboratories Limited and Xenon Pharmaceuticals Inc.
Axsome Therapeutics, Inc. and Xenon Pharmaceuticals Inc.: SG&A Spending Patterns Compared
Cost Management Insights: SG&A Expenses for Verona Pharma plc and Xenon Pharmaceuticals Inc.
Selling, General, and Administrative Costs: Amneal Pharmaceuticals, Inc. vs Xenon Pharmaceuticals Inc.
Bausch Health Companies Inc. vs Amicus Therapeutics, Inc.: SG&A Expense Trends
SG&A Efficiency Analysis: Comparing Amicus Therapeutics, Inc. and Viridian Therapeutics, Inc.